Teva Set To Start Phase III Oral Laquinimod Trial
Submitted by art on Fri, 2007-11-30 08:28.
Teva Pharmaceutical Industries Ltd. and Active Biotech AB have begun enrolling patients in the Phase III clinical trial of oral laquinimod for the treatment of relapsing-remitting multiple sclerosis. The companies plan to include 1,000 patients in the trial, which will last 2-3 years.
This is probably the study listing, but it does not seem to be updated to indicate they are enrolling yet (they updated it after I pointed this out to them).
I contacted Teva and got
I contacted Teva and got confirmation that the clinicaltrials.gov listing is correct and they forgot to update it. Should be fixed shortly if you are interested in participating.
***
Art Mellor, Accelerated Cure Project for MS, art-msnews -at- acceleratedcure.com